New cryovials with integral septum for cryopreservation of pfspz vaccine and pfspz challenge products
Active Grant Awarded Last action
- Award ID
- SB1AI195021
- Recipient
-
Sanaria Inc. UEI YLF2SS2NYGC5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,000,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 6% complete
- Place of performance
- Rockville, MD 20850, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Sanaria Inc. a grant of $1 million on September 18, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The award funds production of new cryovials with an integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products. The work supports Sanaria's stated mission to produce, license, and market Plasmodium falciparum sporozoite malaria vaccines. Final PfSPZ manufacturing steps include adding product to vials and cryopreservation, and PfSPZ products are vialed in screwcap cryovials. The program funds biomedical research in infectious, immunologic, and allergic diseases. Place of performance is Rockville, Maryland 20850. The period of performance ends August 31, 2029, and the full $1 million is obligated under this award.
Description
- Abstract
- Sanaria's mission is to produce, license and market plasmodium falciparum (PF) sporozoite (SPZ) vaccines against malaria that prevent malaria infection and transmission in individuals, including travelers, and can be used in malaria elimination programs. The goal of this proposal is the production of new cryovials for pfspz to facilitate the mission. Despite annual investments of >$4B in malaria control, malaria killed more people annually in africa in 2020-2023 than did covid-19. In 2023 there were 263M clinical cases and 597,000 deaths caused by malaria worldwide. RTS, S/ AS01 malaria vaccine was recommended in 2021 by who on the basis of preventing hospitalizations (17%), severe malaria (32%), and deaths (9%) in a pilot implementation program. R21, a biosimilar, is considered by who to provide similar protection. These existing tools are inadequate: there is an urgent need for a vaccine with high vaccine efficacy (VE) that prevents malaria infection to support malaria elimination. Our 1ST generation radiation-attenuated vaccine, sanaria® pfspz vaccine, was safe and well tolerated in 5-month- to 61-year-olds in 21 clinical trials in 9 countries, 6 in africa. IT induced 92%-100% VE against controlled human malaria infection and significant VE against intense PF transmission in field trials in africa for at least 18-21 months without boosting, including in women who became pregnant. Sanaria's 2ND generation chemo-attenuated vaccine, pfspz-cvac, is 5-8 times more potent than pfspz vaccine, but has safety issues. Sanaria's 3RD generation genetically attenuated vaccine, pfspz- LARC2 vaccine, is expected to be safe and 5-10 times more potent and less expensive than pfspz vaccine. Final steps in manufacturing of all pfspz vaccines are addition of final product to vials and cryopreservation. Pfspz products are vialed in screwcap cryovials. Post-thaw handling of screwcap cryovials for dilution and preparation of syringes must occur in an aseptic environment like a biological safety cabinet. This is not suitable nor acceptable for a commercialized malaria vaccine. No available cryovial meets specifications for pfspz products. We designed a novel cryovial that, like standard vaccine vials, has a septum, enabling use anywhere, and that can be stored at cryogenic temperatures. For a previous version of this vial, we successfully filed a patent application, submitted a drug master file (for vials) to FDA, filled vials with vaccine and initiated clinical trials. However, the vials produced for US by SIO2 materials science had a particulates problem unacceptable to FDA and were associated with less infectious/potent pfspz than pfspz in screwcap vials (discovered in clinical trials). SIO2 filed for bankruptcy and is no longer involved. In this project we will work with both primary and back-up companies, incorporate design improvements, manufacture vials and caps that do not have a particulates problem and support pfspz potency like current screwcap vials. With critical funding not typically supported by phase II/IIB grants, this crpp grant will facilitate development, production, and use of the integral septum cryovials needed for saving lives of those at risk of malaria.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $1,000,000 |
Quick answers
Who received award SB1AI195021?
SB1AI195021 was awarded to Sanaria Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 18, 2026.
How much is award SB1AI195021 worth?
$1,000,000 has been obligated on SB1AI195021.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award